Latest Breaking News On - Immix biopharma inc - Page 7 : comparemela.com

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

United statesVaishali sanchorawalaHeather landauSusan balImmix biopharma incAmyloidosis programBoston university school of medicineMemorial sloan kettering cancer centerAmerican society for hematologyUniversity of alabama at birminghamVirtual eventBoston university schoolAssistant professorAnnual meetingOrphan drug designation

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U S Patient Dosing

NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance72 patients previously dosed with NXC-201 ex-U.S.First CAR-T program for light-chain .

United statesGrand viewIlya rachmanGabriel morrisMike moyerLos angelesMeeting of the european society for bloodDrug administrationExchange commissionAmerican society of hematologyClinical cancer researchImmix biopharma incInternational myeloma societyCompany contactView researchAmerican society for gene

Immix Biopharma, Inc : Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U S Patient Dosing

Immix Biopharma, Inc : Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U S Patient Dosing
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesRheinland pfalzMike moyerGabriel morrisIlya rachmanClinical cancer researchImmix biopharma incDrug administrationMeeting of the european society for bloodAmerican society of hematologyExchange commissionView researchNexcella incAmerican society for geneInternational myeloma societyCompany contact

Immix Biopharma (IMMX) Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U S Patient Dosing

Immix Biopharma (IMMX) Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U S Patient Dosing
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesIlya rachmanInternational myeloma societyDrug administrationAmerican society of hematologyImmix biopharma incClinical cancer researchAmerican society for geneImmix biopharmaInvestigational new drugChief executive officerAmerican societyAnnual meetingAnnual american societyCell therapy

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U S Patient Dosing

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing

United statesIlya rachmanGabriel morrisAmerican society of hematologyMeeting of the european society for bloodView researchImmix biopharma incClinical cancer researchInternational myeloma societyDrug administrationAmerican society for geneImmix biopharmaInvestigational new drugChief executive officerAmerican societyAnnual meeting